RxDoctor Payments Data

Patrick Berry, MD

Family Medicine · Scottsboro, ALNPI 1023671120

Payments from drug & device makers

$1,366in general payments, 2019–2025

Across 81 payments — averaging $16.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$319
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$224
  • AstraZeneca$175
  • GSK$109
  • Vanda Pharmaceuticals Inc.$66
  • Lilly USA, LLC$66
  • plus $408 from 12 others

What the payments were for

  • Food & beverage$1,366100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,366 in reported general payments places this provider in the 60th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$24,158
Medicare patients
106
Services billed
447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban274$100,000
MounjaroTirzepatide75$91,391
OzempicSemaglutide75$68,976
JardianceEmpagliflozin67$66,972
Trelegy ElliptaFluticasone/Umeclidin/Vilanter77$49,079
FarxigaDapagliflozin Propanediol59$42,089
LinzessLinaclotide65$41,102
RexultiBrexpiprazole15$35,036
TrulicityDulaglutide31$29,613
XareltoRivaroxaban55$16,975
RybelsusSemaglutide15$14,783
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$11,457
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen578$10,761
BrilintaTicagrelor77$9,756
KerendiaFinerenone11$7,749

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$66$121,005106 claims
Novo NordiskOzempic, Rybelsus, Levemir$42$88,591104 claims
AstraZenecaFarxiga, Brilinta$175$51,845136 claims
GSKTrelegy Ellipta$109$49,07977 claims
AbbVieLinzess$52$41,10265 claims
Otsuka America Pharmaceutical, Inc.Rexulti$319$35,03615 claims
BayerKerendia$17$7,74911 claims
Astellas Pharma US IncMyrbetriq$62$7,14415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Scottsboro

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →